课题基金 / 基金详情

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): Intensive vs liberalized phosphate control in hemodialysis recipients

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): Intensive vs liberalized phosphate control in hemodialysis recipients
终末期肾病试验 (TARGET) 中的两个磷酸盐目标:血液透析受者的强化磷酸盐控制与自由化磷酸盐控制
批准号:
306984
负责人:
Wald Ron
金额:
$12.27万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2014
资助国家:
加拿大
项目状态:
已结题
起止时间:
2014-03-01 至 2016-03-01

项目摘要

项目成果

Wald Ron的其他基金

相似基金

相关文献

中文摘要
翻译
血液中的高磷酸盐(P)水平几乎普遍见于需要透析的慢性肾衰竭患者。这些高P水平被认为是使患者易患心血管疾病和死亡的原因。因此,几乎所有的
英文摘要
High phosphate (P) levels in the blood are almost universally seen among patients with chronic kidney failure who require dialysis. These high P levels are thought to predispose patients to cardiovascular disease and death. For this reason, almost all dia
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis (GUARD-1)
  • 批准号:
    489351
  • 项目类别:
    Operating Grants
  • 资助金额:
    $41.24万
  • 财政年份:
    2023
  • 负责人:
    Wald Ron
  • 依托单位:
Pragmatic randomised trial of High Or Standard PHosphAte Targets in End-stage kidney disease - PHOSPHATE Canada (TARGET 2)
  • 批准号:
    391022
  • 项目类别:
    Operating Grants
  • 资助金额:
    $111.18万
  • 财政年份:
    2018
  • 负责人:
    Wald Ron
  • 依托单位:
STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI)
  • 批准号:
    322799
  • 项目类别:
    Operating Grants
  • 资助金额:
    $85.78万
  • 财政年份:
    2015
  • 负责人:
    Wald Ron
  • 依托单位:
STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI)
  • 批准号:
    313923
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2014
  • 负责人:
    Wald Ron
  • 依托单位:
海外基金